Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for type 2 diabetes mellitus (T2DM), improving glycaemic control through multiple mechanisms, including enhanced insulin secretion, delayed gastric emptying, and appetite suppression [1,2]. Here, GLP1R is linked to type 2 diabetes mellitus.